test

Maysa Abu-Khalaf MBBS, MD

Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences

Research Interests

Clinical trials evaluating novel agents for the treatment of breast; Ovarian and endometrial cancers; PI3K-mTOR inhibitors; HER-2 targeted therapies; Angiogenesis


Research Summary

Dr. Abu-Khalaf's major research interest is designing and conducting clinical trials evaluating novel treatments for breast, ovarian and endometrial cancers.

Extensive Research Description

Dr. Abu-Khalaf works in close collaboration with members of the Departments of Surgery, Therapeutic Radiology and Diagnostic Radiology to develop integrated clinical programs for patients with breast and gynecologic cancers. She is a member of the the Yale Cancer Center Developmental Therapeutics program. Dr.Abu-Khalaf designs and conducts early phase clinical trials evaluating novel treatment strategies for patients with breast and gynecologic cancers.


Selected Publications

  • Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20;27(21):3430-6. Epub 2009 May 26.
  • Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar;16(3):697-702. Epub 2009 Jan 9.

Edit Profile